Abstract
Renée C.A. Leenen, Esmée F.H. Mulder, Sebastiaan Remmers, Ivo I. de Vos, Kirsi Talala, Rebecka Arnsrud-Godtman, Elly Den Hond, Arnauld Villers, Gregoire Pionas, Luis Llane, Marcos Lujan, Giuseppe Gorini, Donella Puliti, Maciej Kwiatkowski, Stephen Wyler, Chris Bangma, Fritz H. Schroder, Anssi Auvinen, Monique J. Roobol
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The Lancet Commission on prostate cancer: planning for the surge in cases
10.1016/s0140-6736(24)00651-2 · 2024
Screening and prostate-cancer mortality in a randomized European study
10.1056/nejmoa0810084 · 2009
European study of prostate cancer screening - 23-year follow-up
10.1056/nejmoa2503223 · 2025
Prostate cancer early detection in the European Union and UK
10.1016/j.eururo.2024.07.019 · 2025
Unresolved referenced work
Kept as external metadata until matched
Early detection of prostate cancer in the European Union: combining forces with PRAISE-U
10.1016/j.eururo.2023.08.002 · 2023
Unresolved referenced work
Kept as external metadata until matched
Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial
10.1001/jama.2024.3841 · 2024
The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate
10.1080/21681805.2021.1881612 · 2021
Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men
10.1016/j.eururo.2023.11.013 · 2024
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
10.1016/s1470-2045(21)00348-x · 2021
A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial
10.1002/ijc.33940 · 2022
Unresolved referenced work
Kept as external metadata until matched
First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years: population based cohort study
10.1136/bmj-2025-085029 · 2025
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
10.1016/s0140-6736(14)60525-0 · 2014
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
10.1016/j.eururo.2019.02.009 · 2019
Determining the cause of death in randomized screening trial(s) for prostate cancer
10.1111/j.1465-5101.2003.04402.x · 2003
Assessment of causes of death in a prostate cancer screening trial
10.1002/ijc.23126 · 2008
Prostate cancer and socioeconomic status in the Finnish randomized study of screening for prostate cancer
10.1093/aje/kww084 · 2016
Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality
10.1080/21681805.2017.1411392 · 2018
Why do men refuse or attend population-based screening for prostate cancer?
10.1093/pubmed/22.3.312 · 2000
Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees
10.1002/cncr.24680 · 2009
Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial
10.1111/j.1464-410x.2010.09165.x · 2010
Psychosocial determinants of socioeconomic inequalities in cancer screening participation: a conceptual framework
10.1093/epirev/mxq018 · 2011
Determinants of non-participation in population-based breast cancer screening: a systematic review and meta-analysis
2022
Factors promoting breast, cervical and colorectal cancer screenings participation: a systematic review
10.1002/pon.5997 · 2022
Inequalities and risk factors related to non-participation in colorectal cancer screening programmes: a systematic review
10.1093/eurpub/ckaa203 · 2021
Sociodemographic disparities in incidence rates of advanced and low-risk prostate cancer as a proxy for diagnostic activity
10.2340/1651-226x.2025.43399 · 2025
Association of nonadherence to cancer screening examinations with mortality from unrelated causes: a secondary analysis of the PLCO cancer screening trial
10.1001/jamainternmed.2018.5982 · 2019
Social determinants of health and US cancer screening interventions: a systematic review
2023
Socio-economic inequalities in breast and cervical cancer screening practices in Europe: influence of the type of screening program
10.1093/ije/dyq003 · 2010
Does an organised screening programme reduce the inequalities in breast cancer survival?
10.1093/annonc/mdr121 · 2012
Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men
2024
Associations between neighbourhood characteristics and participation in a population-based organised prostate cancer testing (OPT) programme: a register-based study of 50-year-old men
10.1371/journal.pone.0322643 · 2025
The impact of interventions to improve attendance in female cancer screening among lower socioeconomic groups: a review
10.1016/j.ypmed.2010.01.007 · 2010
Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)
10.1002/ijc.25278 · 2010
Estimate of opportunistic prostate specific antigen testing in the Finnish randomized study of screening for prostate cancer
10.1016/j.juro.2017.01.048 · 2017
Contamination by opportunistic screening in the European randomized study of prostate cancer screening
10.1111/j.1464-410x.2003.04407.x · 2003
Prostate specific antigen and biopsy contamination in the Göteborg-1 randomized, population-based, prostate cancer screening trial
10.1097/ju.0000000000002835 · 2022
Adjusting for non-compliance and contamination in randomized clinical trials
10.1002/(sici)1097-0258(19970515)16:9<1017::aid-sim508>3.0.co;2-v · 1997
Advancing mammographic screening among underserved groups: a systematic review and meta-analysis of intervention strategies to increase breast cancer screening uptake
10.3389/phrs.2025.1607873 · doi-reference
The Finnish prostate cancer screening trial: analyses on the screening failures
10.1002/ijc.29300 · doi-reference
Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: analysis of the Finnish randomized study of screening for prostate cancer
10.1002/ijc.32129 · doi-reference
Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
10.1016/j.eururo.2013.08.005 · doi-reference
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
10.1016/j.eururo.2009.07.018 · doi-reference
Efficacy of interventions intended to increase lung cancer screening rates: a systematic review and meta-analysis
10.1007/s11606-024-09097-8 · doi-reference